UY38145A - Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano - Google Patents
Moduladores de sting (estimulador de genes de interferón) a base de ciclopentanoInfo
- Publication number
- UY38145A UY38145A UY38145A UY38145A UY38145A UY 38145 A UY38145 A UY 38145A UY 38145 A UY38145 A UY 38145A UY 38145 A UY38145 A UY 38145A UY 38145 A UY38145 A UY 38145A
- Authority
- UY
- Uruguay
- Prior art keywords
- stimulator
- cyclopentane
- interferon genes
- sting modulators
- compounds
- Prior art date
Links
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 title 2
- 108010050904 Interferons Proteins 0.000 title 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Compuestos de la fórmula general (I): o una sal farmacéuticamente aceptable del mismo, procesos para la preparación de estos compuestos, composiciones que contiene estos compuestos, y los usos de estos compuestos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862643467P | 2018-03-15 | 2018-03-15 | |
US201862666204P | 2018-05-03 | 2018-05-03 | |
US201862742532P | 2018-10-08 | 2018-10-08 | |
US201962809990P | 2019-02-25 | 2019-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38145A true UY38145A (es) | 2019-10-31 |
Family
ID=66103038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY38145A UY38145A (es) | 2018-03-15 | 2019-03-13 | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano |
Country Status (24)
Country | Link |
---|---|
US (4) | US10538542B2 (es) |
EP (1) | EP3765474B1 (es) |
JP (1) | JP7266942B2 (es) |
KR (1) | KR20200131878A (es) |
CN (1) | CN111918871A (es) |
AU (1) | AU2019234043A1 (es) |
BR (1) | BR112020018593A2 (es) |
CA (1) | CA3093631C (es) |
CL (1) | CL2020002352A1 (es) |
CR (1) | CR20200382A (es) |
DO (1) | DOP2020000160A (es) |
EC (1) | ECSP20057847A (es) |
ES (1) | ES2923298T3 (es) |
IL (1) | IL277278A (es) |
MA (1) | MA52012A (es) |
MX (1) | MX2020009587A (es) |
NI (1) | NI202000058A (es) |
PE (1) | PE20210412A1 (es) |
PH (1) | PH12020551486A1 (es) |
RU (1) | RU2020130048A (es) |
SG (1) | SG11202008102VA (es) |
TW (1) | TWI741268B (es) |
UY (1) | UY38145A (es) |
WO (1) | WO2019175776A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
TWI741268B (zh) * | 2018-03-15 | 2021-10-01 | 美商輝瑞股份有限公司 | 干擾素基因刺激劑(sting)的環戊烷為主體之調節劑 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
BR112022005463A2 (pt) * | 2019-09-25 | 2022-06-14 | Pfizer | Moduladores poli-heterocíclicos de sting (estimulador de genes de interferon) |
TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
US11964978B2 (en) * | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
JP6462006B2 (ja) * | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingのモジュレーターとしての環式ジヌクレオチド |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
TWI741268B (zh) * | 2018-03-15 | 2021-10-01 | 美商輝瑞股份有限公司 | 干擾素基因刺激劑(sting)的環戊烷為主體之調節劑 |
-
2019
- 2019-03-11 TW TW108108048A patent/TWI741268B/zh not_active IP Right Cessation
- 2019-03-11 US US16/297,910 patent/US10538542B2/en active Active
- 2019-03-12 SG SG11202008102VA patent/SG11202008102VA/en unknown
- 2019-03-12 CA CA3093631A patent/CA3093631C/en active Active
- 2019-03-12 EP EP19717149.9A patent/EP3765474B1/en active Active
- 2019-03-12 RU RU2020130048A patent/RU2020130048A/ru unknown
- 2019-03-12 MX MX2020009587A patent/MX2020009587A/es unknown
- 2019-03-12 WO PCT/IB2019/052009 patent/WO2019175776A1/en active Application Filing
- 2019-03-12 MA MA052012A patent/MA52012A/fr unknown
- 2019-03-12 JP JP2020548916A patent/JP7266942B2/ja active Active
- 2019-03-12 BR BR112020018593-0A patent/BR112020018593A2/pt not_active IP Right Cessation
- 2019-03-12 CN CN201980019494.9A patent/CN111918871A/zh active Pending
- 2019-03-12 ES ES19717149T patent/ES2923298T3/es active Active
- 2019-03-12 CR CR20200382A patent/CR20200382A/es unknown
- 2019-03-12 PE PE2020001412A patent/PE20210412A1/es unknown
- 2019-03-12 KR KR1020207029472A patent/KR20200131878A/ko not_active Application Discontinuation
- 2019-03-12 AU AU2019234043A patent/AU2019234043A1/en not_active Abandoned
- 2019-03-13 UY UY38145A patent/UY38145A/es not_active Application Discontinuation
- 2019-12-04 US US16/702,738 patent/US10968242B2/en active Active
-
2020
- 2020-08-25 DO DO2020000160A patent/DOP2020000160A/es unknown
- 2020-08-28 NI NI202000058A patent/NI202000058A/es unknown
- 2020-09-10 IL IL277278A patent/IL277278A/en unknown
- 2020-09-11 CL CL2020002352A patent/CL2020002352A1/es unknown
- 2020-09-12 PH PH12020551486A patent/PH12020551486A1/en unknown
- 2020-09-15 EC ECSENADI202057847A patent/ECSP20057847A/es unknown
-
2021
- 2021-03-03 US US17/190,924 patent/US20210230196A1/en not_active Abandoned
-
2023
- 2023-07-24 US US18/225,589 patent/US20230382932A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2020000160A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
CO2020001220A2 (es) | Compuestos, composiciones y métodos | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
CO2020014217A2 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
CL2021002104A1 (es) | Compuestos, composiciones y métodos. | |
CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
UY36121A (es) | ?pirazolopiridinas y pirazolopirimidinas?. | |
CO2018000224A2 (es) | Compuestos inhibidores de la señalización de la vía de notch | |
UY35362A (es) | Compuestos terapéuticos | |
UY38892A (es) | Moduladores de sting (estimulador de genes de interferón) | |
CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
UY37941A (es) | Derivados de bencimidazol y sus usos | |
CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
ECSP23070418A (es) | Moduladores de sting (estimulador de genes de interferón) | |
UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano | |
AR122310A1 (es) | Moduladores de sting (estimulador de genes de interferón) | |
EA202091913A1 (ru) | Модуляторы sting (стимулятора генов интерферона) на основе циклопентана | |
AR114263A1 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
AR113817A1 (es) | Compuestos útiles para inhibir a cdk7 | |
AR105924A1 (es) | Compuestos terapéuticos y síntesis | |
AR102887A1 (es) | Una triazolopiridazina como modulador de quinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20240513 |